Ambys Medicines Expands Board of Directors with Appointment of Jennifer Cook
14 October 2020 - - US-based cell and gene therapy company Ambys Medicines has appointed Jennifer Cook to its board of directors, the company said.

A highly respected biotechnology and pharmaceutical industry executive, Cook's experience includes senior leadership roles globally and in the US during her 25-year tenure at Roche Pharmaceuticals (OTC: RHHBY) and Genentech, and also serving most recently as chief executive officer at GRAIL, a healthcare company focused on the early detection of cancer.

Cook is currently focused on providing advisory support to senior executives in the healthcare field.

Prior to serving as GRAIL's CEO, Cook held a number of leadership positions with Roche/Genentech, including leading Roche Pharmaceuticals' European commercial business, Global Clinical Operations, US and Global Product Portfolio Management, a US Immunology and Ophthalmology Business Unit, and Market Development.

She was honored as the Woman of the Year by the Healthcare Businesswomen's Association in 2016 and was named one of the Most Influential Women in Business by The San Francisco Business Times in 2012.

Cook holds a BA in Human Biology and MS in Biology from Stanford University, as well as an MBA from the Haas School of Business at University of California, Berkeley. Cook also serves on the boards of directors of Denali Therapeutics and BridgeBio Pharma.

Ambys Medicines is a cell and gene therapy company focused on discovering and developing regenerative and restorative therapies for patients with advanced liver disease.

Ambys is pioneering the application of cell and gene therapy to meet the urgent need for novel treatments for those suffering from severe acute and chronic liver diseases.

Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals (OTC: TKPHF) and is headquartered in South San Francisco, California.